Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma

Trial Profile

Lenalidomide Therapy In Previously Untreated, Advanced Stage Indolent Lymphoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 24 Sep 2015 Status changed from discontinued to withdrawn prior to enrolment,as reported by ClinicalTrials.gov.
  • 22 Sep 2015 Status changed from withdrawn prior to enrolment to discontinued as reported by ClinicalTrials.gov.
  • 05 Mar 2015 Planned End Date changed from 1 Aug 2012 to 1 May 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top